strong end plenti reason continu growth
wednesday morn abbott report middl fairway fourth-quart
result put forth revenu earn guidanc line expect
put take relat specif segment and/or product
expect alway case compani size overal noth
discuss caus us question thesi thesi base revenu growth
top group expect organ
fxn basi earn growth doubl digit even face difficult fx
environ addit invest made key product line freestyl
libr alin mitraclip name slew new product opportun
varieti segment import de-lever give compani strateg
flexibl reflect guidanc model
last point net leverag today stand time build-up cash
solid ebitda expect move closer time time
well think appropri busi therefor believ
begin hear exactli manag plan cash
increas dividend alreadi increas decemb debt paydown
seemingli unlik large-scal seem team radar
movement could chang quickli share buyback either way model
use suggest build-up cash modest interest made believ
wind realiti manag team investor satisfi
thu look forward next month believ end-market demand
remain robust across segment margin expans play pipelin
new product launch continu gain traction back substanti invest
cash flow creat accret opportun believ support current
multipl time forward ep compar three-year averag
time room upsid result number lever compani avail
strong cash flow abbott gone signific de-lever phase throughout
debt/ebitda ratio finish year time billion debt
repurchas throughout year estim billion cash ad
anticip billion year believ compani quickli gain
signific flexibl becom acquir yet though manag number
potenti use compani alreadi rais dividend result nearli
dividend yield manag also dissuad investor call assum
larger organ share repurchas suggest instead build reserv
abbott highli diversifi provid medic devic nutrit pharmaceut product
return equiti ttm
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
med tech multipl remain premium manag commentari nondescript believ
manag continu hunt potenti asset particular believ opportun within
establish pharmaceut report solid except growth recent within medic
technolog piec busi strong perhap hole fill attract asset
add portfolio manag histor savvi acquir pick asset face short-
term pressur attract portfolio synergist busi segment though expect
compani remain patient wait right assetand abbott strong intern product launch
invest support continu strong performancew expect manag continu face capit
alloc question investor throughout year
manag provid solid sale guidanc expect organ constant-curr
growth similar full year organ sale growth support continuing/acceler momentum
sever key busi segment busi line manag expect mid- high-single-digit growth
establish pharmaceut low- midsingle-digit growth nutrit mid- high-single-digit growth
diagnost high-single-digit growth medic devic support double-digit growth sever busi
segment view guidanc achiev beatabl potenti upsid driver stem new product
introduct indic expansionsnam mitraclip libr alin platform
key contribut organ growth includ
diabet continu momentum global adopt freestyl libr abbott expand reimburs
coverag intern unit state benefit on-going launch libr
intern market manag guid launch libr come shortli expect
support segment momentum still manag continu pursu strategi drive
adopt type type patient keep featur devic differ rel
competitor better wors overal adopt fgm cgm system acceler materi
increasingli becom mainstream awar new featur access improv mani
item drive penetr continu
fourth quarter abbott ad global freestyl libr user bring total user base
million made user unit state million intern manag
reiter global patient mix two-third type one-third type patientssometh
expect continu though patient mix like closer look forward
expect diabet segment continu momentum potenti upsid new product launch
libr expand reimburs coverag progress secur pharmaci access
continu focu increas market awar million insulin-us diabet unit state
remain signific opportun player expect libr continu grow year
structur heart semin year structur heart readout coapt trial
demonstr improv clinic outcom includ improv surviv treat mitral
regurgit mitraclip data present septemb tct meet posit impact
mitraclip adopt somewhat limit result still manag highlight strong fourth-
quarter mitraclip sale growth reach million full-year sale acceler
growth third quarter
guidanc larg assum continu mitraclip momentum growth rang
upsid potenti come expand indic reimburs unit state treat
function mitral regurgit fmr mitraclip abbott file expand fmr indic
fourth quarter would expect result coapt trial support posit outcom ultim
acceler mitraclip util drive upsid guidanc addit detail coapt trial
found third-quart result note solid third quarter sustain growth across
diagnost organ fxn includ million rapid diagnost segment
averag continu post growth slightli end -market growth rate team identifi
sever lever drive continu growth move forward sub-seg basi highlight follow
manag note continu run point-of-car busi separ integr
acquir rapid diagnost segment aler team also state saw need
re-establish point-of-car given lacklust growth second quarter
third quarter fourth quarter recent replac leadership
optimist segment regain foot appear issu relat
intern focu custom valu proposit point-of-car wonder move
part crossov disctract aler brought hous along continu tsa
success competitor abbott may impact
lab grew quarter manag call alin launch europ
bright spot solid custom retent share win defin roll-out
next two three quarter team intend round core menu approv requir
acceler adopt mean alin like domest driver revenu
beyond
chang commentari infecti diseas virolog market seen
new market entrant come someth intend monitor move forward
push tri captur share panther fusion system
far influenza season concern manag told us guidanc impli million
million headwind first quarter higher end rang normal
season press team given recent cdc data volume day edit
team continu see season normal slightli better normal
updat model follow quarterli result manag guidanc
sale decreas sale estim billion compar previou estim
billion reflect full-year fx headwind
earn increas earn per share estim account smaller-than-
anticip headwind foreign exchang
sale introduc sale estim billion
earn introduc earn per share estim full year
estim
